Citigroup’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-4,751
| Closed | -$16K | – | 7920 |
|
|
2019
Q4 | $16K | Buy |
4,751
+3,146
| +196% | +$10K | ﹤0.01% | 7039 |
|
|
2019
Q3 | $5K | Buy |
1,605
+340
| +27% | +$956 | ﹤0.01% | 7372 |
|
|
2019
Q2 | $3K | Buy |
1,265
+442
| +54% | +$1.32K | ﹤0.01% | 7595 |
|
|
2019
Q1 | $3K | Buy |
+823
| New | +$3.08K | ﹤0.01% | 7510 |
|
|
2017
Q2 | – | Sell |
-1,054
| Closed | -$5K | – | 7578 |
|
|
2017
Q1 | $5K | Sell |
1,054
-2,258
| -68% | -$21.7K | ﹤0.01% | 6824 |
|
|
2016
Q4 | $37K | Sell |
3,312
-2,688
| -45% | -$25.3K | ﹤0.01% | 6284 |
|
|
2016
Q3 | $56K | Buy |
6,000
+344
| +6% | +$2.88K | ﹤0.01% | 5600 |
|
|
2016
Q2 | $36K | Sell |
5,656
-18,818
| -77% | -$125K | ﹤0.01% | 5783 |
|
|
2016
Q1 | $160K | Buy |
24,474
+13,404
| +121% | +$86.4K | ﹤0.01% | 5301 |
|
|
2015
Q4 | $90K | Buy |
11,070
+11,066
| +276,650% | +$82.7K | ﹤0.01% | 5459 |
|
|
2015
Q3 | $0 | Sell |
4
-3,157
| -100% | -$32.2K | ﹤0.01% | 7934 |
|
|
2015
Q2 | $32K | Buy |
+3,161
| New | +$34.9K | ﹤0.01% | 5824 |
|
|
2015
Q1 | – | Sell |
-62
| Closed | – | – | 7559 |
|
|
2014
Q4 | $0 | Buy |
+62
| New | +$355 | ﹤0.01% | 7436 |
|
Citigroup's FOMX Position: Q1 2020 in Review
Citigroup sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 4,751 shares — an estimated $16K sold.
Citigroup first reported a position in FOMX in Q4 2014 and held it in 13 quarters. The position peaked at $160K in Q1 2016. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- Citigroup reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- Citigroup sold 4,751 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $16K.
- Citigroup first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q4 2014 and held it in 13 quarters.
- Citigroup's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $160K in Q1 2016.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on Citigroup's 13F filing for Q1 2020, filed 12 May 2020.